Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
NCT06681220
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Participants will receive either a combination of oral Stenoparib at the highest tolerated dose with oral Temozolomide 40mg daily or standard of care Lurbinectedin for 21-day cycles. The Dose limiting toxicity period will be 1 cycle of 21 days.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Relapsed Small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- March 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- VA Palo Alto Health Care System, Palo Alto, CA · Palo Alto, CA
Indiana · 1
- Richard L. Roudebush VA Medical Center, Indianapolis, IN · Indianapolis, IN
North Carolina · 1
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC · Salisbury, NC
Pennsylvania · 2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA · Philadelphia, PA
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA · Pittsburgh, PA
Texas · 1
- Michael E. DeBakey VA Medical Center, Houston, TX · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.